References
Amarin Corporation. (2008) Amarin to commence phase II trial with AMR101 in age associated memory impairment. January 2010, http://www.amarincorp.com/investor_relations/press-releases/2008/2008-commence-phase2-amr101-age-assoc-mem-impairment.htmlaccessed 6 May 2010.
Burgin, A. et al (2009) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotechnology 28(1): 63–72.
Helicon Therapeutics. (2008) Helicon study of HT-0712 on primate memory formation reveals significant enhancement. 22 July, http://www.helicontherapeutics.com/cgi-bin/main.pl?section=News;page=Press_releases, accessed 6 May 2010.
Nowotny, H. (2008) Insatiable Curiosity: Innovation in a Fragile Future, Translated by M. Cohen. Cambridge, MA: MIT.
Quednow, B.B. (2010) Ethics of neuroenhancement: A phantom debate. BioSocieties 5 (1): 153–156.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nadler, R., Reiner, P. A call for data to inform discussion on cognitive enhancement. BioSocieties 5, 481–482 (2010). https://doi.org/10.1057/biosoc.2010.30
Published:
Issue Date:
DOI: https://doi.org/10.1057/biosoc.2010.30